Edward Pershing - Feb 17, 2024 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
Director
Signature
/s/ Edward Pershing
Stock symbol
PVCT
Transactions as of
Feb 17, 2024
Transactions value $
-$125,000
Form type
4
Date filed
2/20/2024, 11:12 AM
Previous filing
Feb 16, 2024
Next filing
Feb 28, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT 8% Unsecured Convertible Promissory Note Options Exercise -$125K $1.54M Feb 17, 2024 Series D-1 Convertible Preferred Stock 47.2K $2.86 Direct F3, F4
transaction PVCT Series D-1 Convertible Preferred Stock Options Exercise $0 +47.2K +4.91% $0.00 1.01M Feb 17, 2024 Common Stock 472K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F2 The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
F3 The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "2022 Note") at any time while the 2022 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2022 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2022 Note. The 2022 Note was issued pursuant to the Issuer's 2022 Financing.
F4 On February 17, 2024, the 2022 Note was converted into 47,180 shares of Series D-1 Preferred Stock.